From substance-induced psychosis to schizophrenia: Predictors of treatment response and transition to chronic psychotic illness-A systematic review.

Schizophr ResMar 24, 2026 (epub)
Clinical ResearchPsychiatry

Valerio Ricci, Stefania Chiappini, Giovanni Martinotti et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined predictors of treatment response and progression to chronic psychotic illness in substance-induced psychotic disorders (SIPDs). It included 27 studies representing approximately 33,500 patients, with follow-up ranging from 1 month to 15.5 years. Moderate-certainty evidence linked symptom onset within 24–48 h of substance use with favorable response, while prominent negative symptoms and poor premorbid functioning were associated with slower remission or poorer outcomes. The review also identified bimodal response patterns, including rapid remission within 30 days for some patients, and cautioned that several other proposed predictors rest on lower-certainty evidence.

Key findings

  • Symptom onset within 24–48 h of substance use predicted favorable treatment response, supported by moderate-certainty evidence.
  • Prominent negative symptoms predicted slower remission and higher transition to chronic psychotic disorders, with moderate-certainty evidence.
  • Poor premorbid functioning and response patterns involving rapid remission within 30 days versus poorer later outcomes distinguished responders from non-responders.
  • Cannabis-induced and methamphetamine-induced psychosis were highlighted as warranting caution because of higher persistence rates and psychiatric comorbidity.

Why it matters

SIPDs can resolve after substance cessation or persist and progress, making prognosis clinically important. The review identifies temporal onset, negative symptoms, and premorbid functioning as the best-supported factors for distinguishing likely outcomes. Recognising these features may help frame monitoring and prognostic discussions, while the varying certainty of evidence argues against treating less-established predictors as definitive.

What to keep in mind

Evidence certainty varied across predictors; findings on neuroimaging were based on small studies, and several proposed factors had low or very low certainty.

Source

Published in Schizophr Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.